Literature DB >> 16136426

Cardiac amyloidosis diagnosed by endomyocardial biopsy. Clinical, histopathological, immunohistochemical and ultrastructural studies.

Monika Prochorec-Sobieszek1, Zofia T Bilińska, Jacek Grzybowski, Ewa Michalak, Ewa Jakubowska, Małgorzata Sobieszczańska-Małek, Tomasz Deptuch, Ewa Walczak, Teresa Wagner, Michał Walski, Jacek Rózański, Mirosław Kiedrowski, Barbara Lubiszewska, Piotr Hoffman, Witold Rózyłło.   

Abstract

BACKGROUND: The heart is often involved by primary (AL) and familial transthyretin-related (ATTR) amyloidosis. Endomyocardial biopsy is a valuable diagnostic method, useful in detection and recognition of the type of amyloid. AIM: The aim of the study was to determine the type of amyloid deposits found in endomyocardial biopsies, using histochemical, immunohistochemical and ultrastructural methods. The correlations between morphological and clinical parameters were evaluated. METHODS AND
RESULTS: During 1999-2004, endomyocardial biopsy was performed in 41 patients hospitalized in our institution due to heart failure of unknown etiology. Amyloid deposits were revealed in 3 patients, in 2 of them the intraoperative specimens were also taken. The deposits were located in myocardial interstitium as well as in the wall of small vessels. One patient showed deposits in the atrial and pericardial walls. Electron microscopy study revealed amyloid fibers adhering to the basement membranes of the myocardial cells and small vessels. Immunohistochemical staining determined two types of amyloid. A woman aged 42 showed transthyretin-related amyloidosis, most probably hereditary. A woman aged 69 exhibited the light chains amyloidosis (AL-lambda). In contrast, diagnosis was not certain (most probably ATTR) in a 35 year old woman. Essential involvement of the pericardium was observed in two younger patients. They underwent pericardiotomy. The survival time (from diagnosis to death) was one year in the patient with amyloidosis ATTR, 17 days in the patient with the AL type, and 2 years in the patient with amyloidosis of undetermined type.
CONCLUSIONS: Cardiac amyloidosis is associated with poor prognosis. Better recognition of this disease may allow the early diagnosis and institution of modern therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16136426

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  3 in total

1.  Current treatment in cardiac amyloidosis.

Authors:  Ivana Kholová; Josef Kautzner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

2.  Endomyocardial biopsy in patients with cardiomyopathy of unknown origin: does specialized center experience apply to a tertiary care hospital?

Authors:  Ulrich Tebbe; Karin Bramlage; Fiete John; Dirk Härtel; Ralf Felgendreher; Kathrin Machalke; Reinhard Kandolf; Peter Bramlage
Journal:  BMC Res Notes       Date:  2016-10-10

3.  A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor.

Authors:  Muhammad Mufti; Omkar Marathe
Journal:  J Hematol (Brossard)       Date:  2018-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.